Topic: chronic lymphocytic leukemia

35. Copiktra

Previously jilted by Infinity Pharmaceuticals and AbbVie, Copiktra has seen a rough road to its approval as the first dual inhibitor of PI3K-delta and PI3K-gamma.
Genentech illustration for Venclexta release

7. Venclexta

Venclexta’s road to market was a speedy one, notching three breakthrough drug designations, orphan drug designation and priority review status before nabbing an accelerated approval in April.